{"symbol":"BMY","fiscalQuarter":"Q4-2022","reportDate":"2023-02-02","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q4-2022","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 2.16%","keyNumbers":[{"metric":"EPS","actual":"$1.82","expected":"N/A","surprise":"+6.25%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the continued strength of their key products.","They expressed confidence in their pipeline but acknowledged market challenges.","The focus remains on innovation and maintaining competitive positioning."],"summary":"Overall, management conveyed a sense of cautious optimism regarding their product performance. They emphasized the importance of their pipeline while recognizing external market pressures."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a positive surprise in EPS, which contributed to a 2.16% increase in stock price. The management's cautious optimism reflects confidence in their product pipeline despite ongoing market challenges. Investors may view this as a sign of resilience in the company's operations.","metaDescription":"Bristol Myers Squibb (BMY) Q4 2022 earnings: EPS beat by 6.25%. Stock up 2.16%. Full breakdown."}}